Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Diabetes mellitus is a group of a metabolic disorder caused when the body is unable to produce required quantity of Insulin. Insulin is a hormone secreted by beta cells of the islet of Langerhans of the pancreas. Various symptoms associated with diabetes disorder include recurrent urination, increased thirst, and hunger. Diabetes can cause much chronic complication if left untreated. Some of them include acute complications like diabetic ketoacidosis, chronic kidney failure, foot ulcers, and damage to the eyes.
Oral antidiabetic drugs have the advantages of convenience, quickness, and easy access, and are being accepted by patients. Manufacturers of oral antidiabetic drugs are also developing to produce drugs with better effects, and the global oral hypoglycemic drug market will continue to grow.
The global growth of the oral antidiabetic drug market is mainly due to the increased prevalence of diabetic patients worldwide. This growth has continued to occur in developing countries such as India and China. Also, factors leading to an increase in the global diabetes population include sedentary lifestyles, obesity, an increase in the elderly population, and lagging healthcare services. However, the high cost of the drug is expected to limit the growth of the global oral antidiabetic market. The increase in the number of pharmaceutical companies and the emergence of advanced technologies are the key factors driving the growth of this market.
This report offers an overview of the market trends, drivers, and barriers with respect to the China Oral Antidiabetic Drugs market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Oral Antidiabetic Drugs market. Detailed analysis of key players, along with key growth strategies adopted by Oral Antidiabetic Drugs industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Biocon
Novo Nordisk
Sunpharma
Abbott
Pfizer
Merck
Sanofi
Novartis
Eli Lilly
By Type:
Sulfonylureas
Meglitinides
Alpha-glucosidase inhibitors
By End-User:
Hospitals
Clinics
Others
By Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Oral Antidiabetic Drugs Market
-
1.3 Market Segment by Type
-
1.3.1 China Oral Antidiabetic Drugs Market Size and Growth Rate of Sulfonylureas from 2016 to 2027
-
1.3.2 China Oral Antidiabetic Drugs Market Size and Growth Rate of Meglitinides from 2016 to 2027
-
1.3.3 China Oral Antidiabetic Drugs Market Size and Growth Rate of Alpha-glucosidase inhibitors from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 China Oral Antidiabetic Drugs Market Size and Growth Rate of Hospitals from 2016 to 2027
-
1.4.2 China Oral Antidiabetic Drugs Market Size and Growth Rate of Clinics from 2016 to 2027
-
1.4.3 China Oral Antidiabetic Drugs Market Size and Growth Rate of Others from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 North China Oral Antidiabetic Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 Central China Oral Antidiabetic Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 South China Oral Antidiabetic Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 East China Oral Antidiabetic Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.5 Northeast China Oral Antidiabetic Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.6 Southwest China Oral Antidiabetic Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.7 Northwest China Oral Antidiabetic Drugs Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Oral Antidiabetic Drugs Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Commercial Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Oral Antidiabetic Drugs by Major Types
-
3.4.1 Market Size and Growth Rate of Sulfonylureas
-
3.4.2 Market Size and Growth Rate of Meglitinides
-
3.4.3 Market Size and Growth Rate of Alpha-glucosidase inhibitors
4 Segmentation of Oral Antidiabetic Drugs Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Oral Antidiabetic Drugs by Major End-Users
-
4.4.1 Market Size and Growth Rate of Oral Antidiabetic Drugs in Hospitals
-
4.4.2 Market Size and Growth Rate of Oral Antidiabetic Drugs in Clinics
-
4.4.3 Market Size and Growth Rate of Oral Antidiabetic Drugs in Others
5 Market Analysis by Regions
-
5.1 China Oral Antidiabetic Drugs Production Analysis by Regions
-
5.2 China Oral Antidiabetic Drugs Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on China Economy
6 North China Oral Antidiabetic Drugs Landscape Analysis
-
6.1 North China Oral Antidiabetic Drugs Landscape Analysis by Major Types
-
6.2 North China Oral Antidiabetic Drugs Landscape Analysis by Major End-Users
7 Central China Oral Antidiabetic Drugs Landscape Analysis
-
7.1 Central China Oral Antidiabetic Drugs Landscape Analysis by Major Types
-
7.2 Central China Oral Antidiabetic Drugs Landscape Analysis by Major End-Users
8 South China Oral Antidiabetic Drugs Landscape Analysis
-
8.1 South China Oral Antidiabetic Drugs Landscape Analysis by Major Types
-
8.2 South China Oral Antidiabetic Drugs Landscape Analysis by Major End-Users
9 East China Oral Antidiabetic Drugs Landscape Analysis
-
9.1 East China Oral Antidiabetic Drugs Landscape Analysis by Major Types
-
9.2 East China Oral Antidiabetic Drugs Landscape Analysis by Major End-Users
10 Northeast China Oral Antidiabetic Drugs Landscape Analysis
-
10.1 Northeast China Oral Antidiabetic Drugs Landscape Analysis by Major Types
-
10.2 Northeast China Oral Antidiabetic Drugs Landscape Analysis by Major End-Users
11 Southwest China Oral Antidiabetic Drugs Landscape Analysis
-
11.1 Southwest China Oral Antidiabetic Drugs Landscape Analysis by Major Types
-
11.2 Southwest China Oral Antidiabetic Drugs Landscape Analysis by Major End-Users
12 Northwest China Oral Antidiabetic Drugs Landscape Analysis
-
12.1 Northwest China Oral Antidiabetic Drugs Landscape Analysis by Major Types
-
12.2 Northwest China Oral Antidiabetic Drugs Landscape Analysis by Major End-Users
13 Major Players Profiles
-
13.1 Biocon
-
13.1.1 Biocon Company Profile and Recent Development
-
13.1.2 Market Performance
-
13.1.3 Product and Service Introduction
-
13.2 Novo Nordisk
-
13.2.1 Novo Nordisk Company Profile and Recent Development
-
13.2.2 Market Performance
-
13.2.3 Product and Service Introduction
-
13.3 Sunpharma
-
13.3.1 Sunpharma Company Profile and Recent Development
-
13.3.2 Market Performance
-
13.3.3 Product and Service Introduction
-
13.4 Abbott
-
13.4.1 Abbott Company Profile and Recent Development
-
13.4.2 Market Performance
-
13.4.3 Product and Service Introduction
-
13.5 Pfizer
-
13.5.1 Pfizer Company Profile and Recent Development
-
13.5.2 Market Performance
-
13.5.3 Product and Service Introduction
-
13.6 Merck
-
13.6.1 Merck Company Profile and Recent Development
-
13.6.2 Market Performance
-
13.6.3 Product and Service Introduction
-
13.7 Sanofi
-
13.7.1 Sanofi Company Profile and Recent Development
-
13.7.2 Market Performance
-
13.7.3 Product and Service Introduction
-
13.8 Novartis
-
13.8.1 Novartis Company Profile and Recent Development
-
13.8.2 Market Performance
-
13.8.3 Product and Service Introduction
-
13.9 Eli Lilly
-
13.9.1 Eli Lilly Company Profile and Recent Development
-
13.9.2 Market Performance
-
13.9.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure China Oral Antidiabetic Drugs Market Size and Growth Rate of Sulfonylureas from 2016 to 2027
-
Figure China Oral Antidiabetic Drugs Market Size and Growth Rate of Meglitinides from 2016 to 2027
-
Figure China Oral Antidiabetic Drugs Market Size and Growth Rate of Alpha-glucosidase inhibitors from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2021
-
Figure Market Share by Type in 2027
-
Figure China Oral Antidiabetic Drugs Market Size and Growth Rate of Hospitals from 2016 to 2027
-
Figure China Oral Antidiabetic Drugs Market Size and Growth Rate of Clinics from 2016 to 2027
-
Figure China Oral Antidiabetic Drugs Market Size and Growth Rate of Others from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2021
-
Figure Market Share by End-User in 2027
-
Figure North China Oral Antidiabetic Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Central China Oral Antidiabetic Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South China Oral Antidiabetic Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure East China Oral Antidiabetic Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast China Oral Antidiabetic Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Southwest China Oral Antidiabetic Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northwest China Oral Antidiabetic Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Oral Antidiabetic Drugs Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2020
-
Figure Market Share of TOP 5 Players in 2021
-
Figure Market Share of TOP 6 Players from 2016 to 2021
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Map of China
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Oral Antidiabetic Drugs
-
Figure Development Trends of Different Types
-
Table Commercial Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Oral Antidiabetic Drugs by Different Types from 2016 to 2027
-
Table Consumption Share of Oral Antidiabetic Drugs by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Sulfonylureas
-
Figure Market Size and Growth Rate of Meglitinides
-
Figure Market Size and Growth Rate of Alpha-glucosidase inhibitors
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Oral Antidiabetic Drugs by Different End-Users from 2016 to 2027
-
Table Consumption Share of Oral Antidiabetic Drugs by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Hospitals
-
Figure Market Size and Growth Rate of Clinics
-
Figure Market Size and Growth Rate of Others
-
Table China Oral Antidiabetic Drugs Production by Regions
-
Table China Oral Antidiabetic Drugs Production Share by Regions
-
Figure China Oral Antidiabetic Drugs Production Share by Regions in 2016
-
Figure China Oral Antidiabetic Drugs Production Share by Regions in 2021
-
Figure China Oral Antidiabetic Drugs Production Share by Regions in 2027
-
Table China Oral Antidiabetic Drugs Consumption by Regions
-
Table China Oral Antidiabetic Drugs Consumption Share by Regions
-
Figure China Oral Antidiabetic Drugs Consumption Share by Regions in 2016
-
Figure China Oral Antidiabetic Drugs Consumption Share by Regions in 2021
-
Figure China Oral Antidiabetic Drugs Consumption Share by Regions in 2027
-
Table North China Oral Antidiabetic Drugs Consumption by Types from 2016 to 2027
-
Table North China Oral Antidiabetic Drugs Consumption Share by Types from 2016 to 2027
-
Figure North China Oral Antidiabetic Drugs Consumption Share by Types in 2016
-
Figure North China Oral Antidiabetic Drugs Consumption Share by Types in 2021
-
Figure North China Oral Antidiabetic Drugs Consumption Share by Types in 2027
-
Table North China Oral Antidiabetic Drugs Consumption by End-Users from 2016 to 2027
-
Table North China Oral Antidiabetic Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure North China Oral Antidiabetic Drugs Consumption Share by End-Users in 2016
-
Figure North China Oral Antidiabetic Drugs Consumption Share by End-Users in 2021
-
Figure North China Oral Antidiabetic Drugs Consumption Share by End-Users in 2027
-
Table Central China Oral Antidiabetic Drugs Consumption by Types from 2016 to 2027
-
Table Central China Oral Antidiabetic Drugs Consumption Share by Types from 2016 to 2027
-
Figure Central China Oral Antidiabetic Drugs Consumption Share by Types in 2016
-
Figure Central China Oral Antidiabetic Drugs Consumption Share by Types in 2021
-
Figure Central China Oral Antidiabetic Drugs Consumption Share by Types in 2027
-
Table Central China Oral Antidiabetic Drugs Consumption by End-Users from 2016 to 2027
-
Table Central China Oral Antidiabetic Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Central China Oral Antidiabetic Drugs Consumption Share by End-Users in 2016
-
Figure Central China Oral Antidiabetic Drugs Consumption Share by End-Users in 2021
-
Figure Central China Oral Antidiabetic Drugs Consumption Share by End-Users in 2027
-
Table South China Oral Antidiabetic Drugs Consumption by Types from 2016 to 2027
-
Table South China Oral Antidiabetic Drugs Consumption Share by Types from 2016 to 2027
-
Figure South China Oral Antidiabetic Drugs Consumption Share by Types in 2016
-
Figure South China Oral Antidiabetic Drugs Consumption Share by Types in 2021
-
Figure South China Oral Antidiabetic Drugs Consumption Share by Types in 2027
-
Table South China Oral Antidiabetic Drugs Consumption by End-Users from 2016 to 2027
-
Table South China Oral Antidiabetic Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure South China Oral Antidiabetic Drugs Consumption Share by End-Users in 2016
-
Figure South China Oral Antidiabetic Drugs Consumption Share by End-Users in 2021
-
Figure South China Oral Antidiabetic Drugs Consumption Share by End-Users in 2027
-
Table East China Oral Antidiabetic Drugs Consumption by Types from 2016 to 2027
-
Table East China Oral Antidiabetic Drugs Consumption Share by Types from 2016 to 2027
-
Figure East China Oral Antidiabetic Drugs Consumption Share by Types in 2016
-
Figure East China Oral Antidiabetic Drugs Consumption Share by Types in 2021
-
Figure East China Oral Antidiabetic Drugs Consumption Share by Types in 2027
-
Table East China Oral Antidiabetic Drugs Consumption by End-Users from 2016 to 2027
-
Table East China Oral Antidiabetic Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure East China Oral Antidiabetic Drugs Consumption Share by End-Users in 2016
-
Figure East China Oral Antidiabetic Drugs Consumption Share by End-Users in 2021
-
Figure East China Oral Antidiabetic Drugs Consumption Share by End-Users in 2027
-
Table Northeast China Oral Antidiabetic Drugs Consumption by Types from 2016 to 2027
-
Table Northeast China Oral Antidiabetic Drugs Consumption Share by Types from 2016 to 2027
-
Figure Northeast China Oral Antidiabetic Drugs Consumption Share by Types in 2016
-
Figure Northeast China Oral Antidiabetic Drugs Consumption Share by Types in 2021
-
Figure Northeast China Oral Antidiabetic Drugs Consumption Share by Types in 2027
-
Table Northeast China Oral Antidiabetic Drugs Consumption by End-Users from 2016 to 2027
-
Table Northeast China Oral Antidiabetic Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast China Oral Antidiabetic Drugs Consumption Share by End-Users in 2016
-
Figure Northeast China Oral Antidiabetic Drugs Consumption Share by End-Users in 2021
-
Figure Northeast China Oral Antidiabetic Drugs Consumption Share by End-Users in 2027
-
Table Southwest China Oral Antidiabetic Drugs Consumption by Types from 2016 to 2027
-
Table Southwest China Oral Antidiabetic Drugs Consumption Share by Types from 2016 to 2027
-
Figure Southwest China Oral Antidiabetic Drugs Consumption Share by Types in 2016
-
Figure Southwest China Oral Antidiabetic Drugs Consumption Share by Types in 2021
-
Figure Southwest China Oral Antidiabetic Drugs Consumption Share by Types in 2027
-
Table Southwest China Oral Antidiabetic Drugs Consumption by End-Users from 2016 to 2027
-
Table Southwest China Oral Antidiabetic Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Southwest China Oral Antidiabetic Drugs Consumption Share by End-Users in 2016
-
Figure Southwest China Oral Antidiabetic Drugs Consumption Share by End-Users in 2021
-
Figure Southwest China Oral Antidiabetic Drugs Consumption Share by End-Users in 2027
-
Table Northwest China Oral Antidiabetic Drugs Consumption by Types from 2016 to 2027
-
Table Northwest China Oral Antidiabetic Drugs Consumption Share by Types from 2016 to 2027
-
Figure Northwest China Oral Antidiabetic Drugs Consumption Share by Types in 2016
-
Figure Northwest China Oral Antidiabetic Drugs Consumption Share by Types in 2021
-
Figure Northwest China Oral Antidiabetic Drugs Consumption Share by Types in 2027
-
Table Northwest China Oral Antidiabetic Drugs Consumption by End-Users from 2016 to 2027
-
Table Northwest China Oral Antidiabetic Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Northwest China Oral Antidiabetic Drugs Consumption Share by End-Users in 2016
-
Figure Northwest China Oral Antidiabetic Drugs Consumption Share by End-Users in 2021
-
Figure Northwest China Oral Antidiabetic Drugs Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Biocon
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Biocon
-
Figure Sales and Growth Rate Analysis of Biocon
-
Figure Revenue and Market Share Analysis of Biocon
-
Table Product and Service Introduction of Biocon
-
Table Company Profile and Development Status of Novo Nordisk
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novo Nordisk
-
Figure Sales and Growth Rate Analysis of Novo Nordisk
-
Figure Revenue and Market Share Analysis of Novo Nordisk
-
Table Product and Service Introduction of Novo Nordisk
-
Table Company Profile and Development Status of Sunpharma
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sunpharma
-
Figure Sales and Growth Rate Analysis of Sunpharma
-
Figure Revenue and Market Share Analysis of Sunpharma
-
Table Product and Service Introduction of Sunpharma
-
Table Company Profile and Development Status of Abbott
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Abbott
-
Figure Sales and Growth Rate Analysis of Abbott
-
Figure Revenue and Market Share Analysis of Abbott
-
Table Product and Service Introduction of Abbott
-
Table Company Profile and Development Status of Pfizer
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer
-
Figure Sales and Growth Rate Analysis of Pfizer
-
Figure Revenue and Market Share Analysis of Pfizer
-
Table Product and Service Introduction of Pfizer
-
Table Company Profile and Development Status of Merck
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck
-
Figure Sales and Growth Rate Analysis of Merck
-
Figure Revenue and Market Share Analysis of Merck
-
Table Product and Service Introduction of Merck
-
Table Company Profile and Development Status of Sanofi
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi
-
Figure Sales and Growth Rate Analysis of Sanofi
-
Figure Revenue and Market Share Analysis of Sanofi
-
Table Product and Service Introduction of Sanofi
-
Table Company Profile and Development Status of Novartis
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis
-
Figure Sales and Growth Rate Analysis of Novartis
-
Figure Revenue and Market Share Analysis of Novartis
-
Table Product and Service Introduction of Novartis
-
Table Company Profile and Development Status of Eli Lilly
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly
-
Figure Sales and Growth Rate Analysis of Eli Lilly
-
Figure Revenue and Market Share Analysis of Eli Lilly
-
Table Product and Service Introduction of Eli Lilly
-
